ASGT Annual Meeting


		Attendee Information ASGT Fourth Annual Meeting May 30-June 3, 2001, Seattle, Washington

Meeting Information \| Program at a Glance \| Preliminary Program Schedule Exhibitors and Supporters \| Home

Preliminary Program Schedule

Wednesday, May 30
Thursday, May 31
Friday, June 1
Saturday, June 2
Sunday, June 3

Plenary Session III 8:30 a.m. – 9:30 a.m.
	Keynote Speaker: Michael Phelps, PhD
Break 9:30 a.m. – 10:00 a.m.
Concurrent Scientific Symposia 10:00 a.m. – 12:00 p.m.
	Symposium 5: Genetic Diseases II: Metabolic Disorders Chair: Katherine High Speakers:
		Ji-Wen Yoon– Control of type 1 Diabetes by a novel gene therapy Lawrence Chan – Liver-directed gene transfer for treating disorders of lipid metabolism Paul Khaveri – Advances in gene transfer to the skin Seng Cheng – Gene therapy strategies for effective and sustained correction of lysososmal storage lesions in Fabry disease

	Symposium 6: Neural Disorders I: Neurodegeneration Chair: Fred H. Gage Speakers:
		Mark Tuszynski – Growth factor gene therapy for Alzheimer’s disease Patrick Aebischer – Lentiviral vectors as tools for models and treatment of neurodegenerative diseases Jacques Mallet – CNS gene therapy: Improvement of vector design

	Symposium 7: Infectious Diseases Chair: Harriet Robinson Speakers:
		Richard Morgan – Gene therapy for infectious disease: Clinical findings and new directions Don Kohn – Gene therapy for HIV using hemotopoietic stem cells Denise Doolan – DNA-based vaccines against malaria: from the lab to the clinic Margaret Liu – Gene-based vaccines and immunotherapies for infectious diseases

	Symposium 8: Cancer Gene Therapy II: Immunotherapy Speakers:
		Drew Pardoll – Cancer immunotherapy via genetic modification of dendritic cells and their hematopoietic progenitors Eli Gilboa – Tumor RNA transfected dendritic cells: From cancer vaccination to antigen discovery Suezanne Parker – Cancer immunotherapy for the new millennium Claudio Bordignon – Gene therapy of human immunodefiencies

Simultaneous Oral Presentations 1:30 p.m. – 4:00 p.m.

Workshops 1:30 p.m. – 4:00 p.m.
	Workshop 12: Vector Production Moderator: Estuardo Aguilar-Cordova Speakers:
		Fraser Wright – Scale up of a helper virus-free process for AAV vector manufacture Brian Donahue – Large scale production of AAV vectors Morrey Atkinson – Developing GMP production systems for AAV and non-viral gene therapy vectors Richard Snyder – AAV vector production using stable packaging and producer cell lines

	Workshop 13: Amplicons Moderators: Joseph Glorioso, Bernard Roizman Speakers:
		Yoshi Saeki – Improved HSV amplicon vector system: potential and versatility Cornel Fraefel – Recent developments on HSV-1 amplcons and HSV/AAV hybrid vectors Craig Strathdee – Stable gene transfer using HSV amplicon vectors Howard Federoff – Amplicon vector gene transfer to evaluate nervous system function Joseph Glorioso – Treatment of sensory neuron disease using NSV gene vectors Bernard Roizman – The strategy behind the assembly of the herpes simplex virus genome: implications for its use in gene therapy or ablation of cancer cells

	Workshop 14: Immunological Hurdles to Gene Therapy Moderator: James Wilson Speakers:
		Karen Jooss – Factors influencing immunogenicity of recombinant AAV vectors Roland Herzog – Immune response against factor IX in murine and canine models of gene transfer James MacArthur – Dissecting the humoral response to AAV Hans-Peter Kiem – Nonmyeloablative immunosuppressive regimen prolongs in vivo persistence of gene-modified autologous T cells in a nonhuman primate model James Wilson – Innate and acquired immune responses to adenovirus

	Workshop 15: Regulation Moderators: Hermann Bujard, Helen Blau Speakers:
		Timothy Clackson – Gene and cell therapies regulated by dimerizer drugs Ron Evans – Nuclear receptor-based gene switch technology Fred Gage – Regulation of gene expression by novel steroid receptors: Bombyx Mori Hermann Bujard – Controlling genes in vivo via tetracyclines: Aspects of kinetics and longevity of gene expression Helen Blau – Regulatable gene expression: critical to the future of gene therapy

	Workshop 16: Novel Technologies II Moderators: Barrie Carter, W. Pim Stemmer Speakers:
		Bruce Sullenger – Therapeutic RNAs for gene therapy applications Sanjiv Gambhir – Non-invasive imaging of gene therapy in living subjects Volker Schellenberger – Generation of enzymes with novel properties by directed evolution W. Pim Stemmer – Molecular breeding of genes and viruses for gene therapy

Exhibits Open 4:00 p.m. – 7:00 p.m.

Poster Sessions 4:30 p.m. – 7:00 p.m.

HSV Amplicon Dinner and Colloquium (ticketed session) 7:00 p.m. – 10:00 p.m.
	Chair: Xandra Breakefield, PhD This session will include a social hour, dinner and scientific presentations/discussion that focus on innovations in HSV amplicon vectors. Tickets are $20 and a cash bar will be available. Please register for this meeting in advance. This event is supported by Cantab, Genzyme, MediGene, Inc. and Prestwick Scientific Capital, Inc.

Corporate Symposium 7:00 p.m. – 10:00 p.m.
	Aventis – Progress in Clinical Trials with Angiogenic Gene Therapy Session Co-Chairs: Dr. Francois Meyer and Dr. Philippe Prokocimer Room 606-609 The stimulation of new blood vessels growth has been proven to be important in restoring blood flow to the damaged tissues in the preclinical animal studies. To-date, surgery is the mainstay for vascular repair in patients with advanced CAD and PAOD. No drug has been approved for the restoration of the impaired vascular bed. Angiogenic gene therapy provides a hope for the 21st century medical treatment for cardiovascular diseases. This session will review the current approaches in the early phases of gene therapy clinical trials.

		Program schedule for Sunday >